» Articles » PMID: 24146041

CD8+ T Cell Responses to Lytic EBV Infection: Late Antigen Specificities As Subdominant Components of the Total Response

Overview
Journal J Immunol
Date 2013 Oct 23
PMID 24146041
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

EBV elicits primary CD8(+) T cell responses that, by T cell cloning from infectious mononucleosis (IM) patients, appear skewed toward immediate early (IE) and some early (E) lytic cycle proteins, with late (L) proteins rarely targeted. However, L Ag-specific responses have been detected regularly in polyclonal T cell cultures from long-term virus carriers. To resolve this apparent difference between responses to primary and persistent infection, 13 long-term carriers were screened in ex vivo IFN-γ ELISPOT assays using peptides spanning the two IE, six representative E, and seven representative L proteins. This revealed memory CD8 responses to 44 new lytic cycle epitopes that straddle all three protein classes but, in terms of both frequency and size, maintain the IE > E > L hierarchy of immunodominance. Having identified the HLA restriction of 10 (including 7 L) new epitopes using memory CD8(+) T cell clones, we looked in HLA-matched IM patients and found such reactivities but typically at low levels, explaining why they had gone undetected in the original IM clonal screens. Wherever tested, all CD8(+) T cell clones against these novel lytic cycle epitopes recognized lytically infected cells naturally expressing their target Ag. Surprisingly, however, clones against the most frequently recognized L Ag, the BNRF1 tegument protein, also recognized latently infected, growth-transformed cells. We infer that BNRF1 is also a latent Ag that could be targeted in T cell therapy of EBV-driven B-lymphoproliferative disease.

Citing Articles

Coeliac disease as a model for understanding multiple sclerosis.

Drosu N, Bjornevik K, Cortese M, Levy M, Sollid L Nat Rev Neurol. 2024; 20(11):685-690.

PMID: 39379493 DOI: 10.1038/s41582-024-01025-y.


Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice.

Escalante G, Reidel I, Mutsvunguma L, Cua S, Tello B, Rodriguez E Front Immunol. 2024; 15():1445209.

PMID: 39346922 PMC: 11427267. DOI: 10.3389/fimmu.2024.1445209.


Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation.

Sagou K, Sato Y, Okuno Y, Watanabe T, Inagaki T, Motooka Y PLoS Pathog. 2024; 20(2):e1011954.

PMID: 38300891 PMC: 10833513. DOI: 10.1371/journal.ppat.1011954.


Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus.

Boni M, Rieble L, Munz C Viruses. 2022; 14(12).

PMID: 36560713 PMC: 9782805. DOI: 10.3390/v14122709.


Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis.

Yap L, Wong A, Paterson I, Young L Cancers (Basel). 2022; 14(23).

PMID: 36497262 PMC: 9740547. DOI: 10.3390/cancers14235780.


References
1.
Steven N, Annels N, Kumar A, Leese A, Kurilla M, Rickinson A . Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997; 185(9):1605-17. PMC: 2196300. DOI: 10.1084/jem.185.9.1605. View

2.
Saulquin X, Bodinier M, Peyrat M, Hislop A, Scotet E, Lang F . Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing. Eur J Immunol. 2001; 31(3):708-15. DOI: 10.1002/1521-4141(200103)31:3<708::aid-immu708>3.0.co;2-5. View

3.
Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S . Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood. 1997; 90(6):2390-7. View

4.
Feederle R, Neuhierl B, Baldwin G, Bannert H, Hub B, Mautner J . Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes. J Virol. 2006; 80(19):9435-43. PMC: 1617231. DOI: 10.1128/JVI.00473-06. View

5.
Zuo J, Currin A, Griffin B, Shannon-Lowe C, Thomas W, Ressing M . The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009; 5(1):e1000255. PMC: 2603334. DOI: 10.1371/journal.ppat.1000255. View